A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 AN ANTI-CD22 X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY IN COMBINATION WITH ODRONEXTAMAB AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY IN PATIENTS WITH AGGRESSIVE

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Aggressive B-cell Non-hodgkin Lymphoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Confirmations patients have a type of aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    2. Patient should be willing to undergo mandatory tumor biopsies
    3. Patient is willing and able to comply with clinic visits and study-related procedures

You may not be eligible for this study if the following are true:

    1. Prior allogeneic stem cell transplantation or solid organ transplantation
    2. Patients who have received prior treatment with anti-CD20 x anti-CD3 bispecific antibody, such as odronextamab
    3. Diagnosis of mantle cell lymphoma (MCL)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.